VBI VACCINES INC. news, videos and press releases
For more news please use our advanced search feature.
VBI VACCINES INC. - More news...
VBI VACCINES INC. - More news...
- Thinking about buying stock in Arena Group, Dunxin Financial Holdings, Nano-X Imaging, VBI Vaccines, or SuRo Capital?
- VBI Vaccines Reports Second Quarter 2023 Financial Results
- VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
- VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
- Thinking about buying stock in VBI Vaccines, Blue Water Biotech, Xpeng Inc, Riot Platforms, or D-Wave Quantum?
- VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
- VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
- VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
- Thinking about buying stock in Oncolytics Biotech, Joby Aviation, VERSES AI, TMC the metals company, or VBI Vaccines?
- VBI Vaccines Announces Results of Annual General Meeting
- VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
- VBI Vaccines Announces Poster Presentation at EASL 2023
- VBI Vaccines Reports First Quarter 2023 Financial Results
- VBI Vaccines Appoints Vaughn Himes to Board of Directors
- VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
- VBI Vaccines Reports Full Year 2022 Financial Results
- VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
- VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
- VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
- CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
- VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
- VBI Vaccines to Participate in Upcoming Investor Conferences
- VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
- VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- VBI Vaccines to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
- VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
- VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
- VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
- VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
- Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®